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Type 2 diabetes is associated with higher fracture risk. Diabetes-related conditions may account for this risk. Cardiovascular Health
Study participants (N = 5641; 42.0% men; 15.5% black; 72.8±5.6 years) were followed 10.9 ± 4.6 years. Diabetes was defined as
hypoglycemic medication use or fasting glucose (FG)≥126mg/dL. Peripheral artery disease (PAD) was defined as ankle-arm index
<0.9. Incident hip fractures were from medical records. Crude hip fracture rates (/1000 person-years) were higher for diabetic vs.
non-diabetic participants with BMI <25 (13.6, 95% CI: 8.9–20.2 versus 11.4, 95% CI: 10.1–12.9) and BMI ≥25 to <30 (8.3, 95%
CI: 5.7–11.9 versus 6.6, 95% CI: 5.6–7.7), but similar for BMI ≥30. Adjusting for BMI, sex, race, and age, diabetes was related to
fractures (HR = 1.34; 95% CI: 1.01–1.78). PAD (HR = 1.25 (95% CI: 0.92–1.57)) and longer walk time (HR = 1.07 (95% CI: 1.04–
1.10)) modified the fracture risk in diabetes (HR = 1.17 (95% CI: 0.87–1.57)). Diabetes was associated with higher hip fracture
risk after adjusting for BMI though this association was modified by diabetes-related conditions.
1. Introduction
Type 2 diabetic adults have an approximately 40–70%
increased fracture risk [1, 2] compared to non-diabetic
adults although the mechanism for this is not well estab-
lished. Recent studies found fracture risk is elevated not just
in the older diabetic adults, but also for middle-aged type 2
diabetic adults [3–6]. The risk appears to be equivalent for
both diabetic men and women [7], suggesting an increased
risk in both sexes. Importantly, in older diabetic adults,
their generally higher bone mineral density (BMD) does not
protect them from fracture and they have a higher fracture
rate at an equivalent BMD to non-diabetic adults, which may
potentially be due to their burden of diabetic complications
[8, 9]. Although the higher weight of many type 2 diabetic
patients is likely the main contributor to of their overall
higher BMD [10], at an equivalent body size to a non-
diabetic older adult, type 2 diabetic patients are more likely
to fracture [9]. Therefore, other factors in type 2 diabetes
besides BMD and obesity are likely contributing to the higher
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fracture rates. Identifying factors contributing to the higher
fracture rate in diabetes may ultimately lead to preventative
efforts for fracture in this high-risk population.
Hyperglycemia itself may not directly account for the
increased fracture risk in diabetes [1, 2] and impaired
fasting glucose (IFG), or prediabetes, was not associated with
higher fracture risk in older adults [9]. Emerging evidence
suggests that clinical and subclinical alterations in peripheral
nerve function [11], vascular function [12], and kidney
function [13–15] are related to lower BMD, bone loss, or
fracture in a dose-response manner. These complications
could contribute to the higher fracture risk in diabetes. The
objectives of the current study are to determine if type 2
diabetes or IFG are independently associated with a higher
risk for hip fractures for older white and black men and
women and if diabetes-related conditions contribute to the
risk of hip fracture in older type 2 diabetic adults.
2. Subjects, Materials, and Methods
2.1. Study Population. The CHS is a prospective, multicenter,
cohort study of risk factors for cardiovascular disease
in older community-dwelling adults. The study methods
were previously described in detail [16]. In 1989-1990
(white cohort) and in 1992-1993 (black cohort), a total
of 5888 noninstitutionalized, ambulatory men and women
65 years or older were enrolled from Medicare eligibility
lists in four US communities (Pittsburgh, PA; Hagerstown,
MD; Sacramento, CA; Winston-Salem, NC). Each center’s
institutional review committee approved the study and all
participants gave informed consent prior to exams. Mean
age at enrollment was 73 years (range: 65–100); 58%
were women and 16% were black. Participants underwent
an extensive baseline evaluation, including standardized
clinical examinations, laboratory assessments, physical and
cognitive functioning assessments, and questionnaires on
medical history, health status, and risk factors, components
of which were repeated at annual clinic visits through
1998/99. In 2005/06, the entire surviving CHS cohort was
re-recruited to reevaluate physical and cognitive functioning
for the CHS All Stars examination, an ancillary study to
reassess functional status (median age 85, range 77–102;
66.5% female; 16.6% black) [17]. Phone followup for health
outcomes was conducted every six months throughout the
study and through the present time. Participants with hip
fracture concurrent to motor vehicle accidents (N = 9) or
pathologic fracture (N = 9), missing fasting glucose (N =
64), missing or noncompliant fasting status (N = 159), or
missing information on hypoglycemic medications (N = 6)
were excluded, resulting in 5,641 participants available for
analyses.
2.2. Hip Fractures. Information regarding hospitalizations
was collected every 6 months from participants. To ensure
completeness and verify the accuracy of the self-reported
data, Medicare claims data were also used to identify any
hospitalizations. Incident hip fractures were ascertained
from a comprehensive review of hospitalization records
through June 30, 2005, using International Classification of
Diseases, Ninth Revision codes (ICD-9 codes 820.xx). Only
the first hospitalization for hip fracture was considered and
fractures were excluded if they were the result of excessive
trauma (e.g., motor vehicle accident, ICD-9 E810-E825) or
a pathologic condition (e.g., cancer, ICD-9 733.1). Among
5641 participants, 541 incident hip fractures were identified
over 10.9 ± 4.6 years of followup.
2.3. Diabetes. Baseline and incident diabetes status were
defined based on medication information collected annually
by medications inventories through 1998-1999, and fasting
glucose (≥8 hours) measured on blood samples drawn in
1989-90, 1992-93, and 1996-97. Diabetes at study entry was
defined as hypoglycemic medication use or a fasting glucose
≥126mg/dL (≥7.0mmol/L). Impaired fasting glucose (IFG)
at study entry was defined as ≥100mg/dL (≥6.1mmol/L)
but <126mg/dL (<7.0mmol/L) and no use of insulin or oral
hypoglycemic medications. Participants were considered to
have incident diabetes if either of the following conditions
were met during the period after enrollment through a 1998-
99 assessment: (1) any use of insulin or oral hypoglycemic
medications or (2) fasting glucose ≥126mg/dL. Detailed
methods regarding blood draw, sample storage, quality
assurance, and assay performance were previously described
[18]. At baseline, of the 918 participants with prevalent
diabetes, 361 were taking oral hypoglycemic medications
only, 128 were taking insulin only, 11 were on both insulin
and oral hypoglycemic medications, 417 were not taking
medications, and 1 was missing medication information.
2.4. Body Composition and Physical Function. Body weight
was measured using a calibrated balance beam scale and
height was measured with a wall-mounted stadiometer.
Body mass index (BMI) was calculated in kg/m2. Waist
circumference (cm) was measured at the umbilicus. Physical
function was evaluated by the time in seconds to walk 15 feet
in a corridor from a standing start. Participants self-reported
a history of frequent falls in the past year.
2.5. Ankle-Arm Index. Subclinical peripheral arterial disease
(PAD) was defined as ankle-arm index <0.9 (AAI), measured
as the ratio of the ankle systolic blood pressure to the
arm systolic blood pressure, using a standard protocol [19].
After a five minute rest lying on an examination table,
a standard arm blood pressure cuff was used to measure
systolic blood pressure in the right arm and then each ankle.
After palpating the brachial and posterior tibial arteries and
applying ultrasound gel, a Doppler stethoscope and standard
mercury manometer were used to measure systolic blood
pressure in the right brachial artery and each posterior tibial
artery in rapid succession. The lower value of either the left
or right AAI was used to classify subclinical PAD.
2.6. Additional Covariates. Serum creatinine was measured
using the Kodak Ektachem 700 Analyzer (Eastman Kodak,
Rochester, NY), a colorimetric method. Kidney disease was
defined as creatinine ≥1.5mg/dL in men and ≥1.3mg/dL
in women [20] or an estimated glomerular filtration rate
(eGFR) of <60mL/min/1.73m2 [21]. Fasting serum insulin
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level was measured by solid-phase immunoassay (Diagnostic
Products Corp, Los Angeles, CA). Health histories collected
at baseline included self-reported weight at age 50 years,
current smoking, alcohol consumption, vision problems
(unable to see to drive, to watch TV, or to recognize
someone across a room with or without glasses) and
clinical cardiovascular (CVD) disease (myocardial infarction,
angina, congestive heart failure, claudication, stroke, tran-
sient ischemic attack). From the medication inventory, oral
estrogen use was obtained [22], and participants were asked
if they took any calcium supplements one or more times per
week. Physical activity was calculated in kcal/week from total
self-reported activities, excluding household chores, from the
Minnesota Leisure Time Activities questionnaire [23].
2.7. Statistical Analyses. Univariate differences between DM,
IFG, and normoglycemic groups were evaluated by chi-
square tests for categorical covariates, by t-tests for normal
continuous covariates, and by Mann-Whitney nonparamet-
ric tests for nonnormal continuous covariates, in men and
women separately. Crude hip fracture rates (/1000 person-
years) were determined for normal FG, IFG, and DM groups
and also stratified by BMI categories of <25, ≥25 to <30,
and >30. Cox proportional hazards models were used to
estimate the relative risk (hazard ratio) of hip fracture
associated with glycemic status. The participants’ entry time
into the analysis corresponded to their study enrollment date
with time-at-risk until the earliest of incident hip fracture
or censoring at death, loss-to-followup, or the last day of
adjudicated followup (June 30, 2005). Multivariable models
were adjusted for age, sex, race, BMI, diabetes, subclinical
PAD (AAI < 0.9), and other potential confounders and
mediators listed in the “Additional Covariates” section above.
Sex did not satisfy the proportionality assumption due to
an interaction of time with sex and therefore models were
internally stratified for sex. Covariates described above in the
Methods were retained in the final model if they attenuated
the risk estimate by 10% or more or had a P-value <
0.10. Covariates correlated at r ≥ 0.50 were not entered
simultaneously, but one was entered separately and then the
other separately at the same step of the model, for example,
BMI and waist circumference (r = 0.81); BMI and weight
at age 50 (r = 0.50). For example, BMI was entered in the
final regression model instead of waist circumference given
the high correlation and the stronger relationship of BMI to
hip fracture. Other covariates were not highly correlated, for
example, smoking and subclinical PAD (r = 0.09) and smok-
ing and alcohol use (r = 0.05). Potential effect modification
of race, sex, BMI, and subclinical PAD with both DM and
IFG were evaluated through multiplicative interaction terms
with likelihood ratio tests. Stratified analyses by sex were
performed for certain models a priori. Osteoporosis medica-
tion including bisphosphonates, calcitonin, and raloxifene,
and thiazolidinediones (TZDs) were not used at the 1989-
1990 baseline in any participants. However, a sensitivity
analyses was performed which excluded 236 participants that
took these medications during followup. Because incident
diabetes in the normoglycemic and impaired fasting glucose
groups may have modified the risk estimates for the diabetic
group, a separate sensitivity analysis was done by excluding
incident diabetes cases from these two groups. A sensitivity
analysis was also done by excluding participants with AAI >
1.4, since this may represent vascular calcification and vessel
stiffness. Analyses were performed using Stata software,
version 10.0 (Stata Corp., College Station, Texas).
3. Results
Participants with DM or IFG were more likely men (49.3%
and 46.4% versus 36.4%; P < 0.001) than those with normal
FG (Table 1). Participants with DM and IFG had a higher
weight, a higher BMI, a greater self-reported weight at age 50
years, a higher waist circumference, a higher fasting insulin
level, a lower eGFR (men only), lower physical activity, and
were less likely to use oral estrogen or calcium supplements
(women only) compared to those with normal FG. Addition-
ally, participants with DM were more likely to be black, less
likely to be a current drinker, had slower completion of the
measured walk, and had more diabetes-related conditions
(vision problems, subclinical PAD, prevalent CVD, and renal
insufficiency) than those with normal FG.
Crude hip fracture rates (/1000 person-years) were 9.1
(95% CI: 8.1–10.3) for normal FG, 7.1 (95% CI: 6.1–8.2)
for IFG, and 7.7 (95% CI: 6.0–9.8) for DM. Crude hip
fracture rates were higher for diabetic compared to non-
diabetic participants with BMI <25 (13.4, 95% CI: 8.9–20.2
versus 10.6, 95% CI: 8.5–13.4 IFG and 11.8, 95% CI: 10.1–
13.7 normal FG) and BMI ≥25 to <30 (8.3, 95% CI: 5.7–
11.9 versus 6.3, 95% CI: 5.0–8.0 IFG and 6.8, 95% CI: 5.4–
8.5 normal FG), but were similar for BMI ≥30 (4.1, 95% CI:
2.4–7.0 versus 4.3, 95% CI: 2.9–6.4 IFG and 5.5, 95% CI:
3.5–8.7 normal FG) (Figure 1). The percentage of diabetic
participants with fractures was 10.6% (23/218) for BMI <25,
7.5% (29/385) for BMI ≥25 to <30, and 4.2% (13/313)
for BMI ≥30. The percentage of non-diabetic participants
with fractures was 12.4% (243/1964) for BMI <25, 7.6%
(149/1958) for BMI ≥25 to <30, and 5.6% (44/788) for BMI
≥30.
Diabetes was not significantly related to fractures in
unadjusted models or models adjusted for sex, race, and age.
The addition of BMI to the models adjusted for sex, race,
and age increased the risk of hip fracture in DM participants
(HR = 1.34; 95% CI: 1.01–1.78; Table 2). This indicated that
the DM participants were at higher incidence fracture risk
at an equivalent BMI to participants with normal glycemia.
IFG was slightly protective for fracture in models minimally
adjusted for age, sex, and race though this association was
eliminated after adjusting for BMI and IFG was not shown
to increase the risk of hip fracture (HR = 0.91; 95% CI: 0.75–
1.11) in fully adjustedmodels. These results may indicate that
higher BMI overall in the IFG group is protective for fracture
but once BMI is adjusted for in the models, fracture risk
is similar at an equivalent BMI to participants with normal
glycemia. Excluding participants with incident diabetes (N =
103 from the normoglycemic group and N = 327 from the
IFG group), did not appreciably change these estimates for
DM (HR = 1.32; 95% CI: 1.00–1.76) or IFG (HR = 0.93; 95%
CI: 0.76–1.15). Estimates were similar for diabetic women
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Table 1: Baseline descriptive characteristics by glycemic status for 5,641 women and men in the CHS.
Women (n = 3254) Men (n = 2387)
DM (n = 465) IFG
(n = 1144)
No IFG or
DM
(n = 1645)
DM
(n = 453)
IFG
(n = 991)
No IFG or
DM
(n = 943)
Black race 139 (29.9%)† 162 (14.2%) 248 (15.1%) 84 (18.5%) 100 (10.1%)‡ 142 (15.1%)
Age (years) 72.7 (±5.7) 72.6 (±5.5) 72.4 (±5.3) 72.9 (±5.2) 73.2 (±5.6) 73.5 (±6.1)
Current
smoker
50 (10.8%) 149 (13.0%) 213 (13.0%) 42 (9.3%) 105 (10.6%) 118 (12.5%)
Current
drinker
122 (26.3%)† 535 (46.9%) 777 (47.4%) 189 (41.8%)† 623 (63.2%) 572 (60.9%)
Oral
estrogen use
20 (4.3%)† 102 (8.9%)† 270 (16.4%) NA NA NA
Calcium
supplement
use
73 (15.9%)†
273
(24.1%)†
513 (31.5%) 35 (7.8%) 95 (9.7%) 92 (9.9%)
Height (cm) 159.4 (±6.3) 158.9
(±6.4)
158.7
(±6.1) 173.6 (±6.8) 172.9 (±6.6) 173.0 (±6.5)
Weight (lbs) 165.2 (±32.3)† 154.4
(±31.2)†
141.6
(±28.3)
184.2
(±31.2)†
177.2
(±26.8)† 167.1 (±24.8)
BMI (kg/m2) 29.5 (±5.4)† 27.7 (±5.2)† 25.5 (±4.8) 27.7 (±4.3)† 26.9 (±3.7)† 25.3 (±3.3)
Waist cir-
cumference
(cm)
100.4 (±14.1)† 94.1
(±14.1)†
88.4
(±13.5)
101.2
(±11.2)† 98.8 (±10.0)
† 94.6 (±9.5)
Weight at
age 50 (lbs)
154.7 (±28.7)† 141.2
(±23.1)†
135.3
(±22.1)
184.3
(±29.7)†
172.6
(±24.1)† 167.1 (±21.5)
Fasting
insulin
(IU/mL)
21 (14,31)∗† 14 (11,19)∗† 11 (8,14)∗ 17 (12,28)∗† 14 (10,19)∗† 11 (8,14)∗
Walk time (s
to walk 15 ft)
6.7 (±2.7)† 5.9 (±2.1) 5.9 (±2.3) 6.0 (±3.1)‡ 5.5 (±2.0) 5.5 (±2.2)
Physical
activity
(kcal/wk)∗
210 (0,749)∗†
385
(28,1094)∗‡
495
(79,1193)∗
856
(230,1920)∗‡
917
(306,2166)∗‡
1088
(405,2407)∗
Frequent
falls
33 (7.1%)† 38 (3.3%) 72 (4.4%) 16 (3.6%) 13 (1.3%) 23 (2.5%)
Vision
problem
53 (12.4%)‡ 83 (7.7%) 117 (7.6%) 18 (4.0%) 50 (5.1%) 55 (6.0%)
AAI < 0.90 89 (20.1%)† 123 (11.1%) 180 (11.2%) 102 (23.2%)† 129 (13.2%) 112 (12.0%)
Prevalent
CVD
151 (32.5%)†
237
(20.7%)‡
285 (17.3%) 189 (41.7%)† 285 (28.8%) 290 (30.8%)
High
creatinine
(≥1.5mg/dL
men or
≥1.3mg/dL
women)
37 (8.2%)‡ 52 (4.6%) 70 (4.3%) 55 (12.2%) 108 (10.9%) 95 (10.1%)
eGFR
<60mL/min/
1.73m2
99 (21.9%) 245 (21.4%) 333 (20.2%) 118 (26.5%)‡ 245 (24.7%)‡ 196 (20.8%)
Data are means (±standard deviations) or proportions unless otherwise indicated.
∗Data are medians (25th percentile, 75th percentile).
†P value <0.001. ‡P value <0.05.
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Figure 1: Crude incident hip fracture rate (/1000 person-years) by
BMI category for diabetes mellitus, IFG, and normal FG.
(HR = 1.35; 95% CI: 0.96–1.91) and men (HR = 1.31; 95%
CI: 0.80–2.13), though lower statistical power likely made the
results nonsignificant for these stratified analyses. IFG was
not shown to increase the risk of hip fracture in separate
analyses for women (HR = 0.94; 95% CI: 0.74–1.18) or men
(HR = 0.86; 95% CI: 0.59–1.26). There were no interactions
of race, sex, BMI, or subclinical PAD with glycemic status.
Addition of subclinical PAD (ankle-arm index <0.9)
to the model reduced the HR for DM (1.25 (0.94–1.68)),
rendering the association nonsignificant, and low AAI
was significantly related to hip fracture (1.31 (1.01–1.71)).
Excluding participants with AAI >1.4 (N = 67) did not
change these results. Additional adjustment for current
smoking, current drinking and 15 ft walk time further
decreased the HR for DM (1.17 (0.87–1.58)), though each
to a lesser degree than PAD, and decreased the HR for
subclinical PAD (1.20 (0.92–1.57)) (Table 3). A longer time
to complete the measured walk was significantly related to
hip fracture incidence (1.07 (1.04–1.10)) and further reduced
the HR for DM after the addition of current smoking
and drinking to the models. Results did not change after
excluding 236 participants taking osteoporosis medication
during the followup period, including bisphosphonates,
calcitonin, raloxifene, and thiazolidinediones (TZDs).
4. Discussion
Our results indicate that diabetic participants with similar
BMI as non-diabetic participants were more likely to frac-
ture, particularly in the normal and overweight BMI cate-
gories. DM was associated with 34% higher hip fracture risk
after adjusting for higher BMI in diabetic participants, con-
sistent with previous estimates [1, 2]. One possibility for this
observation is that sicker participants are losing weight due
Table 2: Association of impaired fasting glucose and diabetes
mellitus with incident hip fracture.
No IFG or DM IFG Diabetes
Overall (n) 2588 2135 918
No. of hip
fractures
269 169 65
Person-years 29,462 23,851 8,428
Multivariable HR (95% CI)
Model 1:
Age-sex-race
adjusted
1.0 (ref.)
0.79
(0.65–0.96)
1.05
(0.80–1.39)
Model 2:
Model 1 +
BMI
1.0 (ref.)
0.91
(0.75–1.11)
1.34
(1.01–1.77)
Model 3:
Model 2 + AAI
< 0.9
1.0 (ref.)
0.92
(0.75–1.12)
1.25
(0.93–1.67)
Table 3: Final model for association of impaired fasting glucose and
Diabetes Mellitus with incident hip fracture.∗
HR 95% CI
DM 1.17 0.87–1.57
IFG 0.93 0.76–1.13
AAI, <0.9 1.20 0.92–1.57
BMI, kg/m2 0.93 0.91–0.95
Time for walk, s 1.07 1.04–1.10
∗
Models were internally stratified for sex and adjusted for age, race, current
smoking, and current alcohol use. Clinical cardiovascular disease, use of oral
estrogen, use of calcium supplements, renal insufficiency (either creatinine
≥1.5mg/dL in men/≥1.3mg/dL in women or eGFR <60mL/min/1.73m2),
fasting insulin level, physical activity, history of falls, and vision problems
were not included in the final model since they did not attenuate the HR for
diabetes and were not significantly related to hip fracture.
to advanced illnesses. Higher BMD loss among older diabetic
women from the Health ABC Study was partly due to their
greater weight loss over time [24]. The higher risk of fracture
in the diabetic participants was partially modified by adding
subclinical PAD to the models, which accounted for a reduc-
tion in the risk of fracture and made the primary association
nonsignificant. This finding is important because although
there is much evidence for the higher risk of fracture with
DM [1–9, 25, 26], less is known about the factors that
underlie this increased risk. Nearly all PAD in the elderly is
subclinical, with 98% asymptomatic [19]. Although subclin-
ical PAD is underappreciated clinically [27], it is preventable
[28]. Although our overall attenuation with subclinical
PAD was modest, our results, taken with previous findings
of clinical and subclinical vascular disease associated with
osteoporosis [12, 29–32], suggest that subclinical PAD may
be a contributor to fractures in older diabetic populations. In
the Health ABC Study the higher risk of fracture in diabetes
persisted after adjustment for subclinical PAD [9], though
this population was likely healthier at baseline than partic-
ipants in our study. The association of vascular disease and
osteoporosis may be the result of shared risk factors for which
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we adjusted for in the analyses (e.g., age, smoking) or shared
biologic pathways (e.g., inflammatory cytokines, endoge-
nous sex hormones) [33]. Alternatively, vascular disease may
reduce blood flow to the lower extremities, including the hip,
and modify bone metabolism to lead to osteoporosis.
Additional possible explanations for higher fracture risk
in older adults with diabetes may be disease complications
due to a long disease duration [1, 2, 34, 35], and/or specific
complications such as impaired vision [25, 35] or neurologic
impairments (e.g., neuropathy, stroke) [9, 25, 26, 36].
Further support exists from previous type 1 diabetes studies,
summarized by Strotmeyer et al. [37], which indicate that
lower BMD is associated with type 1 diabetic complications
of nephropathy, neuropathy, and retinopathy. One reason for
our lack of association between IFG and hip fracture may be
that it is not the higher glucose levels per se that increase
fracture risk but rather the diabetes-related conditions.
Previous studies, including several meta-analyses, have also
failed to find an association of IFG and fracture [1, 2, 9].
Falling and impaired motor abilities are more common in
diabetic adults [9, 25, 26, 38, 39], and physical performance
accounted for some of the increased risk for hip fractures in
several cohorts of older adults [40, 41]. Our results indicated
a slight modification of the higher fracture rate in DM once
accounting for the slower walk time in DM participants.
Our study was a large established cohort of black and
white men and women followed for over a decade with
an excellent ascertainment of hip fracture. However, we
did not have a measure of BMD. Participants with higher
BMI likely had a higher BMD as well, given the strong
correlation usually observed between these two measures.
A similar cohort which adjusted for the generally higher
BMD observed in older diabetic adults found that diabetic
participants with similar BMD as non-diabetic participants
were more likely to be at risk for incident fractures and
adding BMD to the models actually increased the strength
of the association of fracture with DM [9]. We did not
have measures of diabetes duration or of peripheral nerve
function. Poor peripheral nerve function may increase the
risk for falls [42] and has been related to lower bone mineral
density [11, 37]. Additionally, we did not assess vitamin D
deficiency, which is associated with osteoporosis and has
been linked to diabetes and vascular disease [43]. TZDs,
although associated with fracture in diabetic women [44],
were introduced late in our study followup period and
our results were unaffected when we excluded participants
using TZDs during the followup period for the fracture
outcome. Furthermore, the use of these medications were
likely not prevalent enough to account for the relationship
of DM and fracture and past studies indicating higher
fracture risk in type 2 diabetic adults were conducted prior
to the introduction and widespread use of TZD medication
[45]. Although we were not able to fully address this issue,
hypoglycemic medication use is important to evaluate in the
context of diabetes and fracture and it is critical to recognize
the potential for confounding by indication. Finally, older
diabetic adults with more severe disease may have been less
likely to participate in our study and this may have made our
risk estimates for fracture more conservative.
Likely diabetes-related conditions account for a portion
of increased fracture risk and potentially BMD changes; how-
ever, these have not been comprehensively evaluated. Our
results indicated that subclinical PAD and slower walking
time be related to a part of the higher risk for hip fracture
in older diabetic adults. PAD is preventable and treatable
[27, 28] and clinical PAD was recently linked to a three-
time higher risk of hip fracture [46]. Other diabetes-related
complications may be important as well and should be
investigated for their role in fractures in older diabetic adults.
Poor physical function in older diabetic adults could also be
improved through physical therapy or exercise interventions.
Potentially, preventing diabetes-related conditions in older
diabetic adults may reduce fractures in this population.
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